Search research articles
Contact Us
Filters
Showing results (81-90 of 151) with videos related to
Page
of 16
Sort By:
Hematological Oncology
|
July 31, 2019
Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach
Alessandra Iurlo, Elena Maria Elli, Francesca Palandri, et al.
Frontiers in Oncology
|
November 4, 2021
Co-Occurrence of Myeloid and Lymphoid Neoplasms: Clinical Characterization and Impact on Outcome. A Single-Center Cohort Study
Cristina Bucelli, Bruno Fattizzo, Daniele Cattaneo, et al.
British Journal of Haematology
|
January 4, 2020
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse
Vittorio Montefusco, Alessandro Corso, Monica Galli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 13, 2011
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi
Teodoro Chisesi, Monica Bellei, Stefano Luminari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 30, 2015
Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi
Francesco Merli, Stefano Luminari, Paolo G Gobbi, et al.
Clinical Case Reports
|
February 18, 2021
A case of aggressive systemic mastocytosis with bulky lymphadenopathy showing response to midostaurin
Mariarita Sciumè, Fabio Serpenti, Simona Muratori, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 21, 2005
ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi
Paolo G Gobbi, Alessandro Levis, Teodoro Chisesi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 12, 2014
CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia
Pietro Bulian, Tait D Shanafelt, Chris Fegan, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 16, 2013
Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemia
Alessandra Tedeschi, Francesca Ricci, Maria Cecilia Goldaniga, et al.
Leukemia & Lymphoma
|
February 9, 2011
Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study
Giovanni D'Arena, Paolo G Gobbi, Chiara Broglia, et al.
Page
of 16
Search research articles
Search
Showing results (81-90 of 151) with videos related to
Sort By:
Page
of 16
Hematological Oncology
|
July 31, 2019
Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach
Alessandra Iurlo, Elena Maria Elli, Francesca Palandri, et al.
Frontiers in Oncology
|
November 4, 2021
Co-Occurrence of Myeloid and Lymphoid Neoplasms: Clinical Characterization and Impact on Outcome. A Single-Center Cohort Study
Cristina Bucelli, Bruno Fattizzo, Daniele Cattaneo, et al.
British Journal of Haematology
|
January 4, 2020
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse
Vittorio Montefusco, Alessandro Corso, Monica Galli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 13, 2011
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi
Teodoro Chisesi, Monica Bellei, Stefano Luminari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 30, 2015
Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi
Francesco Merli, Stefano Luminari, Paolo G Gobbi, et al.
Clinical Case Reports
|
February 18, 2021
A case of aggressive systemic mastocytosis with bulky lymphadenopathy showing response to midostaurin
Mariarita Sciumè, Fabio Serpenti, Simona Muratori, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 21, 2005
ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi
Paolo G Gobbi, Alessandro Levis, Teodoro Chisesi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 12, 2014
CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia
Pietro Bulian, Tait D Shanafelt, Chris Fegan, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 16, 2013
Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemia
Alessandra Tedeschi, Francesca Ricci, Maria Cecilia Goldaniga, et al.
Leukemia & Lymphoma
|
February 9, 2011
Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study
Giovanni D'Arena, Paolo G Gobbi, Chiara Broglia, et al.
Page
of 16